Prognostic Impact of Menopausal Hormone Therapy in Breast Cancer Differs According to Tumor Characteristics and Treatment.
aromatase inhibitor
breast cancer
cohort
menopausal hormone therapy
prognosis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
10
2019
accepted:
16
01
2020
entrez:
3
3
2020
pubmed:
3
3
2020
medline:
3
3
2020
Statut:
epublish
Résumé
This study investigated how a history of menopausal hormone therapy (MHT) impacts clinical outcomes overall and in different subgroups of breast cancer patients. The study included 814 primary breast cancer patients aged ≥50 years in Sweden (2002-2012) with follow-up until 2016. Associations between patient- and tumor characteristics, recurrences, and overall survival were analyzed in relation to MHT. After a median follow-up of 7 years, 119 recurrences, and 111 deaths occurred. Ever MHT (
Identifiants
pubmed: 32117735
doi: 10.3389/fonc.2020.00080
pmc: PMC7015974
doi:
Types de publication
Journal Article
Langues
eng
Pagination
80Informations de copyright
Copyright © 2020 Godina, Ottander, Tryggvadottir, Borgquist, Isaksson and Jernström.
Références
Breast Cancer. 2017 Sep;24(5):643-657
pubmed: 28601917
Lancet. 2019 Sep 28;394(10204):1159-1168
pubmed: 31474332
J Clin Oncol. 2015 Sep 1;33(25):2772-9
pubmed: 26215945
Springerplus. 2014 May 22;3:261
pubmed: 24892005
Breast. 2013 Jun;22(3):344-50
pubmed: 22981738
Arch Surg. 2002 Sep;137(9):1015-9; discussion 1019-21
pubmed: 12215151
Breast Cancer Res Treat. 2015 Jan;149(2):505-15
pubmed: 25556354
Am J Hum Genet. 2007 Aug;81(2):208-27
pubmed: 17668372
Maturitas. 2014 Dec;79(4):442-8
pubmed: 25304746
Climacteric. 2004 Sep;7(3):284-91
pubmed: 15669553
Control Clin Trials. 1998 Dec;19(6):589-601
pubmed: 9875838
Nat Rev Endocrinol. 2017 Apr;13(4):220-231
pubmed: 27716751
Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1464-1473
pubmed: 27461048
Breast Cancer Res. 2008;10(5):R78
pubmed: 18803850
Lancet. 2003 Aug 9;362(9382):419-27
pubmed: 12927427
JAMA. 2002 Jul 17;288(3):321-33
pubmed: 12117397
Eur J Surg Oncol. 2005 Jun;31(5):467-72
pubmed: 15922881
Br J Cancer. 1999 Jul;80(9):1453-8
pubmed: 10424750
Br J Cancer. 2001 Sep 1;85(5):674-7
pubmed: 11531250
Br J Cancer. 2016 Jul 26;115(3):382-90
pubmed: 27280635
Lancet. 2002 Jun 22;359(9324):2131-9
pubmed: 12090977
Cancer Causes Control. 2003 Sep;14(7):673-80
pubmed: 14575365
Br J Cancer. 2005 Aug 22;93(4):392-8
pubmed: 16106246
Prog Mol Biol Transl Sci. 2017;151:1-32
pubmed: 29096890
Menopause. 2016 Nov;23(11):1199-1203
pubmed: 27465718
Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):864-71
pubmed: 18381475
Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1203-12
pubmed: 22564867
Int J Cancer. 2016 May 1;138(9):2098-108
pubmed: 26649645
Breast Cancer Res Treat. 2011 Apr;126(3):749-61
pubmed: 20878463
Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1188-96
pubmed: 19336542
Cancer. 2003 Mar 15;97(6):1387-92
pubmed: 12627501
Int J Environ Res Public Health. 2016 May 11;13(5):
pubmed: 27187426
J Natl Cancer Inst. 2013 Apr 17;105(8):526-35
pubmed: 23543779
Cancer. 2003 Dec 15;98(12):2539-46
pubmed: 14669271
Breast Cancer Res Treat. 2014 Jun;145(2):439-47
pubmed: 24671356
J Clin Oncol. 2007 Oct 1;25(28):4438-44
pubmed: 17785707
Int J Cancer. 2007 May 15;120(10):2202-7
pubmed: 17278089
J Clin Oncol. 2008 Jul 10;26(20):3310-6
pubmed: 18612147
JAMA. 2017 Sep 12;318(10):911-913
pubmed: 28898364
Clin Cancer Res. 2015 Aug 15;21(16):3640-50
pubmed: 25904752
JAMA. 2017 Sep 12;318(10):927-938
pubmed: 28898378
BJOG. 2019 Jan;126(1):55-63
pubmed: 30106241